18^th BIENNIAL EUROPEAN CONFERENCE OF SMDM

Linking Research to Evidence-Based Action for Patients, Providers and Policy Decision Makers
21-23 May 2023, Berlin, Germany. 

Abstract submission system is now closed.

ABSTRACT SUBMISSION GUIDELINES

SMDM is strongly committed to diversity and inclusion. SMDM encourages consideration of diversity in all abstract submissions including (but not limited to) gender, career stage, ethnicity, race, education, region/geographic location etc.

General Information

• Abstracts should not be identical to previously published abstracts.
• Abstracts should report original work that has not been published or accepted for publication in manuscript form prior to abstract submission.
• Abstracts should not have been previously presented at another SMDM conference (European, Asia-Pacific, or North American). Abstracts that have been presented at another SMDM conference are eligible for submission only if they include new aspects of the work (e.g., analyses, results, interpretation).
• The language of the conference will be English. Please submit all abstracts in English.
• Accepted abstracts will be published as submitted on the SMDM European Conference website, in the Conference app and in the online version of the Society’s journal, Medical Decision Making. Changes to submitted abstracts will not be accepted after the extended submission deadline, Monday, 6 February 2023, at 23:59 (CET).
• All submissions will be reviewed by the Scientific Review Committee, and notifications will be sent to presenting authors by late March 2023.
• Accepted abstracts must have at least one presenting author who registers for and attends the European Conference. Author(s) are responsible for expenses associated with the submission and presentation of an abstract.
• Authors or co-authors can be from industry/pharmaceutical companies.
• SMDM welcomes an unlimited number of abstract submissions per presenter. However, a maximum of 2 abstracts will be accepted as oral presentations. Any additional accepted abstracts beyond the 2 oral presentations will be slotted as poster presentations. There is no limit to the number of poster presentations per person.

ABSTRACT CATEGORIES 

Scientific abstracts for oral or poster presentation are welcome in a wide range of topics relevant to medical decision making. For review purposes, submitted abstracts will be grouped in the following categories: 

ELIGIBILITY REQUIREMENTS FOR EUROPEAN STUDENT PRIZE COMPETITION

An abstract will be considered for the European Lee B. Student Prize Competition if it meets the following criteria:

• The presenting author must have been enrolled in an educational program leading to a degree or certificate at the time the abstract was submitted. Examples of qualifying educational programs include professional school, residency, fellowship, or programs leading to degrees such as PhD, MS, MBA, MD, RN, PharmD etc.
• The student must have played a substantive role in the submitted abstract, including the conception and implementation of the research project.
• The status as a student at the time the abstract was submitted must be verified by a sponsoring faculty member. The sponsoring faculty member will be contacted by the SMDM office and asked to attest to the eligibility of the abstract for the student prize competition.
• If accepted for presentation, the student must be the first author of the poster presentation and must present it at the meeting. If the student who is the first author is not able to present at the meeting, the presentation may be given by another author, but it will not be eligible for the Lusted Award. 

INSTRUCTIONS FOR ABSTRACT SUBMISSION

• All abstracts must be submitted through SMDM's online abstract system. The presenting author will receive an email confirmation that the abstract has been successfully submitted.
• The following contact information is required for the Presenting Author: First name, Last name, Department, Institution, Street address, City, State, Country, Phone number and a valid email address. First name, Last name, Institution, City, State, Country and a valid email address are required for all co-authors.
• The presenting abstract author must disclose his or her financial support. This information is required by the Society for Medical Decision Making. This information will not affect the scientific review of the abstract. One of the following presentation preferences must be selected:
• "Oral" presentation, indicating the abstract should be considered for oral presentation only.
• "Oral or Poster" presentation, indicating the author prefers oral presentation of the abstract, but poster presentation is an acceptable alternative.
• "Poster" presentation, indicating the abstract should be considered for poster presentation only. 

ABSTRACT FORMAT

• The title should be brief and should clearly indicate the content of the paper. Abbreviations may not be used in abstracts titles.
• Enter authors' names and institutional affiliations in separate fields. If an author does not have an institutional affiliation, indicate their city, state/province, and country. Omit titles, degree, institutional appointments, street names, and postal codes.
• Each abstract, excluding title and author information, may be no longer than 375 words. 

Organize the body of the abstract as follows:

• Purpose of the study, preferably one sentence.
• Methods used to conduct the research in sufficient detail to evaluate their appropriateness and novelty.
• Results stated in sufficient detail to support conclusions. It is not satisfactory to state “Results will be discussed” or “Data will be presented.”
• Conclusions
• Single space all text with one space between paragraphs.
• Do not use underlining or capitalization for emphasis.
• Simple tables, graphs and figures may be included. The image will be scaled from its original size so the abstract will fit into its allotted space. The size of the scaled image will be the printed size in the final program book.
• There is a limit to 1 image file per abstract. 

PRESENTATION OF ACCEPTED ABSTRACTS

All oral abstract and poster presenters must disclose conflicts of interest or perceived conflicts of interests at the time of presentation. Oral abstract presenters will be asked to include a slide at the beginning of the presentation disclosing potential conflicts of interest or stating that there were no conflicts. Poster presenters will be asked to include a similar statement at the bottom of the poster.

EMBARGO AND PRESS RELEASE POLICY

• SMDM does not place a press embargo on accepted work. However, any promotion of an accepted abstract, prior to its presentation at the SMDM meeting, should mention that the work will be presented at the upcoming SMDM meeting, state the theme of the meeting, and give the dates and location of that meeting.
• Use of product brand names is not permitted.
• Use of trademarks or registered service marks for any organization without their permission (except for clinical citations) will not be permitted. This includes but is not limited to the following examples: American Society of Clinical Oncology®, ASCO®, American Society of Hematology®, ASH®, San Antonio Breast Conference Symposium®, SABCS®, American Society of Microbiology®, ASM®, ICAAC®, DDW®, AASLD®, AGA®, ASGE®, SSAT®. A trademark can only be used to describe an event (e.g., Colorectal Cancer Report from the 40th Annual Meeting of the American Society of Clinical Oncology). These trademarks must be used as narrowly as possible to avoid any confusion that the activity is sponsored by or associated in any way with such organizations or their events.
• Objectivity and fair balance mean that recommendations or emphasis must fairly represent, and be based on, a reasonable and valid interpretation of the information available on the subject (e.g., "On balance the data support the following."). A balanced view of therapeutic options also means that no single product or service is over-represented in the educational activity when other equal but competing products or services are available for inclusion.
• For slide presentations and print materials each slide or key teaching point must state the kind of trial that demonstrates the data being discussed. Slides are not required to state, for example, "Level 1 evidence" (although it is acceptable to include it), but slides are required to include a statement, for example, "Systematic review of 35 RCTs..." or "Case-controlled trial..." that supports what is being discussed and presented within each slide. This is a conventional approach in the tradition of evidence-based medicine and may be viewed at the Oxford Centre for Evidence-Based Medicine.

SUBMISSION PROCESS OVERVIEW

Instructions

• No names or titles should be included in the abstract text. Names will automatically be hidden during the abstract review process and will be automatically inserted and properly formatted upon publication.
• Abstracts may be viewed and modified at any time between submissions and the deadline, using your email and access key.
• Complete all the tasks in any order no later than Monday, 23 January 2023, at 23:59 (CET). 

The following tasks must be completed to submit an abstract. The tasks can be completed in any order. A green check mark will appear when a task is complete.

• Enter contact information for each author.
• Identify the presenting author
• Disclosure: The presenting author must complete a disclosure form
• Identify if this abstract is being submitted for the European Lee B. Lusted Student Competition
• If yes, then enter the Faculty Member’s Contact Information
• Enter abstract text
• Your abstract should be no more than 375 words and have the following guidelines
  • Purpose
  • Methods
  • Results
  • Conclusions
  • Include any images or graphs if necessary
• Review the tasks and ensure all information has been completed
• Click submit button. 

SUPPORT 

For help in submitting an abstract online, contact Mr. Emre Köse, Scientific Programme Coordinator: ekose@kenes.com 

Submit